SPAC Sponsors Reveal 31.5% Baird Medical Stake Nearly Two Years After Deal Close
BDMD sits 36% above its 52-week low of $0.757 on light trading volume (0.4× avg).
Summary
Three SPAC sponsor entities disclosed a combined 31.5% stake in Baird Medical, acquired in the October 2024 business combination but only now publicly reported. The filing surfaces concentrated insider ownership and potential selling pressure against a backdrop of severe financial distress.
Key Events · Ownership and Investor Activity · BDMD
-
SPAC Sponsors Hold 31.5% Combined Stake
Grand Fortune Capital (HK) Co Ltd holds 19.1% (7,004,016 shares), ExcelFin SPAC LLC holds 11.6% (4,249,031 shares), and Grand Fortune Capital LLC holds 0.8% (290,000 shares) of Baird Medical's 36.7M outstanding ordinary shares.
-
Stakes Acquired in October 2024 Business Combination
The shares were obtained through the SPAC merger, including founder/sponsor shares, working capital loan conversions at $10.20 per share, and $2.9M in Series A Preferred Shares convertible into ordinary shares.
-
Delayed Disclosure Raises Governance Concerns
The Schedule 13D was filed on July 28, 2026, nearly two years after the October 2024 business combination, with no prior public disclosure of these ownership stakes.
-
Financial Distress Context
The filing follows a July 27, 2026 amended 20-F showing a $27.5M loss, $0.2M cash, and $42.5M in mostly overdue receivables, heightening concerns about the company's viability and the potential for insider selling.
Analysis · BDMD · Industrial Applications And Services
A Schedule 13D filed nearly two years after the October 2024 business combination discloses for the first time that three SPAC sponsor entities—ExcelFin SPAC LLC, Grand Fortune Capital (HK) Co Ltd, and Grand Fortune Capital LLC—collectively control 31.5% of Baird Medical's ordinary shares. The revelation lands just days after an amended 20-F showed a $27.5M loss, only $0.2M in cash, and $42.5M in mostly overdue receivables. The delayed disclosure and concentrated insider ownership raise governance red flags, while the sizable overhang could weigh on the stock if any of these holders decide to sell.
At the time of this filing, BDMD was trading at $1.03 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $43.5M. The 52-week trading range was $0.76 to $3.75. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.